Your browser does not support iframes.
The opening of the new multi-purpose synthesis plant at Teva’s Croatian site in Savski Marof marks the end of the greatest investment cycle in PLIVA’s history, worth over one billion kuna. The new plant, worth half a billion kuna, will double production capacities in some segments at Savski Marof. More than 95 % of products will be exported to the largest markets around the word.
Dr. Galit Gonen, Teva’s award-winning General Counsel for Europe and Head of Litigation, is featured in PharmaTimes magazine
Pharma Tech Outlook Magazine, an authoritative journal for technological biopharmaceutical developments, published a special edition editorial featuring Guy Hadari, SVP & CIO, Teva Pharmaceuticals.
Teva's German production sites are planning to convert their electricity supplies to 100% renewable energy. By December 2015, they will be using only “green energy”.
In a remarkable achievement, Anna Yarvits, SVP General Manager, Teva Russia & CIS, has been rated as one of the 25 Most Influential Women CEO in Russian Business.
On April 25, a devastating earthquake of 7.9 magnitude hit Nepal and the surrounding areas.
Fourth annual PatientView survey identifies Teva as a “Corporate Star” in the eyes of patients. Making medicines accessible is key to patient groups.
More than 160 employees recently participated in Teva Italia’s V-Day (volunteer-day). The event was held on October 16th at ten different non-profit associations across Italy. The selected organizations deal with key social issues including children from broken families, victims of abuse, families in need of assistance and social integrations of foreign people and the disabled.
His Royal Highness the Prince of Wales invited Richard Daniell to attend a private event hosted by International Health Partners (IHP) at Clarence House in London last week, not a bad way to spend a Friday!
Teva UK Limited’s generics offering, including community pharmacy partnership schemes, services and customer service, has been named the best in the industry at a recent pharmacy awards ceremony.
The President of the Republic of Croatia, Dr. Ivo Josipović, officially opened the new R&D extension for complex molecules and new therapeutic entities at PLIVA, Teva Croatia's Research Institute, on Monday, December 1st, 2014.